Encoded Therapeutics Raises $275M Series F for ETX101

Encoded Therapeutics made a painful operating choice in February 2025: it cut 29% of its staff, narrowed resources around ETX101, and said the restructuring should extend its runway into the third quarter of 2026. Nineteen months later, the company has closed a $275M Series F to carry its lead Dravet syndrome program through pivotal development while building the manufacturing capacity required for a one-time genetic medicine.

GV and another healthcare fund that Encoded did not identify co-led the September 9, 2026 financing. ARCH Venture Partners, Braidwell, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock participated. The transaction gives Encoded capital for a clinical, manufacturing, and regulatory handoff that looks very different from the discovery work on which the company was founded.

What Encoded Therapeutics announced

The Series F will support the pivotal ENDEAVOR Part 2 study of ETX101 in infants and young children with SCN1A-positive Dravet syndrome. It will also fund an expansion study in children and adolescents up to age 18, commercial scale-up of Encoded's internal good manufacturing practice capabilities, and development of ETX301 toward a planned 2027 Investigational New Drug submission for post-amputation neuroma pain.

The company did not disclose the identity of the second co-lead, its valuation, the financing instrument, ownership terms, or individual check sizes. Encoded previously announced a $104M Series C in 2019 and a $135M Series D in 2020. Those two rounds and the new Series F total $514M, but other parts of the company's financing history are not disclosed consistently enough to support a precise lifetime-funding figure.

Why ETX101 is technically different

Dravet syndrome is a severe developmental and epileptic encephalopathy that often begins in infancy. In most affected people, a loss-of-function variant in one copy of the SCN1A gene reduces production of NaV1.1 sodium channels in inhibitory neurons, contributing to seizures and broader developmental, behavioral, motor, and cognitive effects.

Replacing SCN1A directly is difficult because the gene is too large for the standard payload capacity of an adeno-associated virus vector. ETX101 takes a regulatory approach instead. The investigational AAV9 therapy is designed to deliver a cell-selective regulatory element that increases expression from the patient's working SCN1A copy in inhibitory interneurons. It is administered once through an intracerebroventricular injection into cerebrospinal fluid.

That design reflects the platform that co-founders Kartik Ramamoorthi, Ph.D., Encoded's CEO, and Stephanie Tagliatela, Encoded's CSO, began building in 2014. The broader technology searches for regulatory DNA sequences that can control where a therapeutic payload is expressed and at what level, giving the company a way to target particular cells without treating every neuron as the same biological address.

The clinical signal and its limits

The financing followed updated Phase 1/2 POLARIS data presented on September 8 at the European Epilepsy Congress. Encoded reported results from 21 participants across four dose levels, with the data cutoff on August 3, 2026. In the cumulative analysis through Week 52 or the latest visit, dose level 3 participants had a median monthly countable seizure-frequency reduction of approximately 76%, while dose level 4 participants had a median reduction of approximately 60%.

Among the participants who had completed 52 weeks of observation, Encoded reported Month 12 median reductions of approximately 79% for dose level 3, based on 3 participants, and 89% for dose level 4, based on 5 participants. The company also reported continued gains in cognition and adaptive behavior, along with no treatment- or procedure-related serious adverse events through as much as 117 weeks of follow-up. Transaminase elevations occurred in 7 of 21 participants and thrombocytopenia in 3 of 21; Encoded said the events were clinically asymptomatic and resolved.

These are encouraging company-reported interim results from small, open-label cohorts. They do not establish the benefit-risk profile that a larger controlled program and regulators will require. Encoded's pivotal ENDEAVOR Part 2 study plans to evaluate seizure and neurodevelopmental outcomes in 30 infants and young children from 6 months through 4 years of age, with initial data anticipated by the end of 2027.

Manufacturing is part of the product

The Series F does more than buy additional clinical visits. Gene therapy requires the drug substance, analytical methods, quality systems, process controls, and regulatory evidence to mature alongside the trial. A compelling biological signal can still be stranded if the product cannot be made reproducibly, released to specification, and scaled without changing the therapy patients receive.

Encoded has built internal GMP manufacturing capabilities in Research Triangle Park, North Carolina, while keeping its headquarters in South San Francisco. The company says the new capital will support commercial scale-up of that facility. ETX101 has also been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, which is intended to help manufacturing preparation keep pace with accelerated clinical development.

That parallel work matters because the pivotal program and manufacturing process are converging. The closer ETX101 moves toward registration, the less room there is to treat manufacturing as a downstream procurement exercise. Investors are financing a system that must produce clinical evidence and a dependable product record at the same time.

The Dravet market is becoming a modality contest

Encoded is not the only company trying to address the biology beneath Dravet syndrome. Stoke Therapeutics is developing zorevunersen, an antisense oligonucleotide intended to increase functional NaV1.1 protein from the non-mutated SCN1A copy. Biogen paid Stoke $165M upfront for rights outside the United States, Canada, and Mexico, putting a large pharmaceutical partner behind a different route to the same genetic target.

The distinction reaches beyond dosing frequency. Encoded is testing whether one administration can durably change SCN1A expression, while the antisense approach is built around repeat dosing. Safety, durability, developmental benefit, clinical practicality, caregiver burden, manufacturing, and reimbursement will all shape how the market judges those trade-offs. Approved seizure medicines remain part of patient care, but they generally manage symptoms rather than attempt to correct the underlying SCN1A mechanism.

What the $275M changes

The financing arrives after years in which Encoded repeatedly concentrated resources around ETX101. Fierce Biotech reported that the company reduced headcount in 2023 and again by 29% in 2025 as it prioritized the Dravet program. The new capital replaces a short runway with enough balance-sheet capacity to run the pivotal study, expand the age range, prepare manufacturing, and continue a second program.

ETX301 extends the platform into post-amputation neuroma pain by using a vectorized microRNA approach designed to reduce SCN9A expression in pain-sensing neurons. Encoded plans a 2027 IND submission, but the program remains preclinical and its safety and efficacy in people are unproven. The Series F gives the company room to advance ETX301 without blurring the near-term priority around ETX101.

For families, investors, and operators, the next proof will arrive on two clocks. The clinical clock will measure seizure control, neurodevelopment, safety, and durability in larger and more rigorous studies. The manufacturing clock will measure whether Encoded can produce a consistent one-time therapy at the quality and scale a commercial program demands. The company has financed both timelines; the obligation is to make them meet before patient need has to wait for either one.